$GILD Headlines Gilead: Hepatitis C Japan trial meets

New Post Public Reply Private Reply Replies (0) Message Board

Apr 3, 2014 at 10:32 AM

$GILD Headlines

Gilead: Hepatitis C Japan trial meets endpoint 3:43 a.m. Today - MarketWatch.com
Facebook, Biogen, Cal-Maine are stocks to watch 5:21 a.m. March 31, 2014 - Victor Reklaitis
Play-it-safe stock investors may take some risk on jobs 8:30 a.m. March 30, 2014 - Wallace Witkowski
U.S. stocks end week with losses 7:17 p.m. March 28, 2014 - Anora Mahmudova
Bombora watch, the 'momo' chart of pain and 5 reasons to buy Citigroup 8:33 a.m. March 28, 2014 - blogs.marketwatch.com
Nasdaq pullback rife with opportunity 2:07 p.m. March 25, 2014 - The Trading Deck
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - blogs.marketwatch.com
Nasdaq slumps 1.2%, but Dow dips just 0.2%: Stock market live blog recap 3:39 p.m. March 24, 2014 - blogs.marketwatch.com
Biotech has second straight sell-off; sector mutual funds take it on chin 10:40 a.m. March 24, 2014 - blogs.marketwatch.com
Biotech's Friday selloff: Are sector bears growling or just stretching? 5:08 p.m. March 21, 2014 - blogs.marketwatch.com
Newscast: Stocks close lower after late fade 4:26 p.m. March 21, 2014 - MarketWatch
First Solar extends winning streak; Symantec plunges 3:06 p.m. March 21, 2014 - Ben Eisen
Picking stocks to weather any market 1:15 p.m. March 21, 2014 - Mark Hulbert
The Nasdaq has a message to deliver 1:56 p.m. March 20, 2014 - The Trading Deck
Aeropostale slides; Liberty Media drops Sirius plan 4:15 p.m. March 14, 2014 - Saumya Vaishampayan
S&P 500 marks 50th record close; Nasdaq slips as biotechs reverse: Stock market live blog (recap) 4:38 p.m. March 6, 2014 - blogs.marketwatch.com
Winning approval for new drugs may get harder, analyst warns 3:56 p.m. Feb. 28, 2014 - blogs.marketwatch.com
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
When it comes to stocks, play follow the leader 3:54 p.m. Feb. 13, 2014 - The Trading Deck
3D Systems down on weak outlook, CVS quits cigarettes 4:16 p.m. Feb. 5, 2014 - Saumya Vaishampayan

Myriad Genetics (MYGN) Worth Watching: Stock Rises 11.5% - Tale of the Tape 9:25 a.m. Today - Zacks.com
Should You Get Rid of Synageva BioPharma (GEVA) Now? - Tale of the Tape 8:59 a.m. Today - Zacks.com
The Medicines Co. Falls on Angiomax Woes - Analyst Blog 5:30 p.m. April 2, 2014 - Zacks.com
Biotech Giants Now Priced Like Old World Drug Stocks 2:43 p.m. April 2, 2014 - 247WallSt.com
SCYNEXIS Should Treat Its Own Fungus Pre-IPO 2:37 p.m. April 2, 2014 - Seeking Alpha
Celgene Extends Ties with Forma Therapeutics - Analyst Blog 11:40 a.m. April 2, 2014 - Zacks.com
Jim Cramer's Stop Trading: GOOG GILD 11:10 a.m. April 2, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Meet Nasdaq Composite 2.0 10:15 a.m. April 2, 2014 - FOXBusiness
Gilead's HepC Drug Sales May Be More Resilient Than Feared 10:10 a.m. April 2, 2014 - benzinga.com
Gilead (GILD) Leading In Pre-Market Activity 8:16 a.m. April 2, 2014 - TheStreet.com
Large Cap Biotechs Trading With Only Big Pharma P/E Ratios 7:30 a.m. April 2, 2014 - 247WallSt.com
Cramer's Mad Money - Bursting The Bears' Bubble (4/1/14) 5:25 a.m. April 2, 2014 - Seeking Alpha
'Fast Money' Recap: A Market In Higher Gear 5:00 a.m. April 2, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: The Market's Short-Term Memory 8:13 p.m. April 1, 2014 - TheStreet.com
Gilead Sciences Inc (GILD): Today's Featured Drugs Winner 5:00 p.m. April 1, 2014 - TheStreet.com
Update on Pfizer's OTC Nexium 24HR - Analyst Blog 4:30 p.m. April 1, 2014 - Zacks.com
Oxygen Biotherapeutics Up on FDA News - Analyst Blog 3:13 p.m. April 1, 2014 - Zacks.com
3 Stocks Driving The Drugs Industry Higher 1:03 p.m. April 1, 2014 - TheStreet.com
Cubist Rises on Favorable FDA Panel View - Analyst Blog 11:30 a.m. April 1, 2014 - Zacks.com

Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis 8:00 a.m. Today - PR Newswire - PRF
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan 4:30 p.m. April 2, 2014 - BusinessWire - BZX
Critical Alerts For Ford, Castlight Health, Gilead Sciences, Take Two Interactive, and Qihoo 360 Released By InvestorsObserver 9:31 a.m. April 2, 2014 - PR Newswire - PRF
Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo! 12:03 p.m. March 31, 2014 - PR Newswire - PRF
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014 8:30 a.m. March 28, 2014 - BusinessWire - BZX
Gilead's Marketing Application Validated by EMA; Accenture Misses Zack's Consensus Estimate 12:38 a.m. March 28, 2014 - ACCESSWIRE
European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection 4:10 p.m. March 27, 2014 - BusinessWire - BZX
Janssen to Present New Simeprevir Data at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) 8:00 a.m. March 24, 2014 - PR Newswire - PRF
Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case 7:01 a.m. March 24, 2014 - GlobeNewswire
Gilead Sciences Prices Hepatitis C Drug at $84,000; Versartis Commences Trading on the NASDAQ 12:30 a.m. March 24, 2014 - ACCESSWIRE
AHF: Gilead’s ‘Obscene’ $180M Payday for CEO Fuels Shareholder Resolution on Compensation 4:57 p.m. March 17, 2014 - BusinessWire - BZX
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:03 a.m. March 14, 2014 - GlobeNewswire
Idenix Pharmaceuticals Files Patent Infringement Lawsuits Against Gilead Sciences in Europe 7:01 a.m. March 14, 2014 - Thomson Reuters ONE
Investor-Edge.com Most Active Equities Watch List: Staples, Gilead Sciences, Office Depot, and Sprint 8:00 a.m. March 7, 2014 - PR Newswire - PRF
Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar 8:25 a.m. March 6, 2014 - PR Newswire - PRF
Critical Alerts For Baidu.com, Gilead Sciences, Deere, Alexion Pharmaceuticals, and Ford Released By InvestorsObserver 9:31 a.m. March 5, 2014 - PR Newswire - PRF
Gilead Prices $4 Billion of Senior Unsecured Notes 6:15 p.m. March 4, 2014 - BusinessWire - BZX
Insider Trading Profile Alerts for Cisco, Gilead Sciences, Exxon Mobil, Facebook, Microsoft, and Bank of America 8:30 a.m. March 3, 2014 - PR Newswire - PRF
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3 5:00 p.m. Feb. 28, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Endava Facing Securities Fraud Suit; Stocks Down 24%

Endava Hits Rough Patch with Legal Battle Brewing So here we are, watching Endava plc struggle through legal quagmires and tumbling stock prices. Come September 21, 2026, news hit the street: Endava's CFO, Mark Thurston, found himself on administrative leave due to an investigation surrounding some shaky accounting practices. The Audit Committee raised a red flag, and...

JobPlanner Boosts Tools to Shield Margins in Construction

Real-Time Solutions for Real-World Challenges JobPlanner is stepping up its game with some beefed-up financial management tools, and I gotta admit, it's like a lifeline in the raging sea of construction costs. We're talking about a souped-up Real-Time Job Costing Suite tailored for general and specialty contractors who are tired of watching their profits evaporate into...

Chicken Salad Chick Spices Up Holidays With Mary Mistletoe

Dishing Out Holiday Spirit by the Scoop The holiday season's rolling around, and Chicken Salad Chick, this fast-casual joint that's got a bit of a thing for chicken salad, isn't letting the festive season pass by without a splash. They've brought out Mary Mistletoe, a holiday-themed chicken salad offering that just might become your table's centerpiece. "We wanted Mary...

Martin's Holiday Heatwave: Mixing Summer Flavors

Holiday Heatwave Meets Winter Cheer with Martin's Rolls Hold onto your oven mitts, folks, because Martin’s Famous Potato Rolls and Bread is stirring up the winter doldrums with an unexpected twist this holiday season. Forget the old cranberry sauce routine—it’s all about mixing sunny vibes with frosty festivities in their "Very Merry Martin’s: Holiday Heatwave."...

Atrium's Heart Therapies: ATR 1072's Promising Data

Atrium Therapeutics Strikes a Chord with New Data Tuning into the heartbeats of breakthrough developments, Atrium Therapeutics dropped some fresh, nonclinical insights about their latest contender, ATR 1072. This wasn't just any ordinary announcement; it's like when the market hears whispers of a Fed rate adjustment. The venue? The American Heart Association's 2026...

Target Hospitality Readies for Q3 2026 Earnings Reveal

The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...

New Paths Emerge in Thin Film Dewetting Control

The Thin Film Challenge: Decoding Dewetting Ah, dewetting—it's a bit like trying to keep a chocolate bar solid on a scorching summer day. These thin films, they're supposed to hold their own, spread thin and steady. But apply a little heat or a laser, and watch them form tiny islands, like a retreating tide. Now, there's some fresh thinking in the air, straight from...

FirstEnergy Foundation Aims High with New Leadership

Changing the Guard at FirstEnergy Foundation For a company with a hefty footprint across the northeastern United States, FirstEnergy Corp. (NYSE: FE) seems to be diving deep into the philanthropic pool with its recent leadership shuffle. Don Rettig, an experienced figure in the world of corporate philanthropy, is taking the helm as Vice President and President of the...

Ebix and intentyx Tackle AI Security in Regulated Fields

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

Harel Insurance Preps Q3 2026 Earnings Report

Harel's Financial Spotlight: Next Moves on November 23, 2026 Harel Insurance Investments, a bigwig in the Israeli insurance landscape, is about to pull back the curtain on its third quarter 2026 financial report. Come November 23, the numbers will hit the streets, and every investor's gotta be asking: what's the latest play from Harel? Exploring Harel's Strategic...